Status:
COMPLETED
A Study of Bimatoprost 0.01% in the Clinical Setting
Lead Sponsor:
Allergan
Conditions:
Glaucoma, Primary Open Angle
Ocular Hypertension
Eligibility:
All Genders
20+ years
Brief Summary
This is a study of bimatoprost 0.01% (LUMIGAN® 0.01%) in subjects with primary open-angle glaucoma (POAG) or ocular hypertension (OH) who require further treatment for elevated intraocular pressure (I...
Eligibility Criteria
Inclusion
- Diagnosis of primary open-angle glaucoma or ocular hypertension
- Determined by the treating physician to require treatment with bimatoprost 0.01%.
Exclusion
- Previous use of Lumigan® 0.01%
Key Trial Info
Start Date :
May 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2014
Estimated Enrollment :
312 Patients enrolled
Trial Details
Trial ID
NCT01814761
Start Date
May 1 2013
End Date
August 1 2014
Last Update
October 26 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Taichung, Taiwan